

AMENDMENTS TO THE CLAIMS

Please amend the claims as follows:

1. (withdrawn)
- 5 2. (withdrawn)
3. (withdrawn)
4. (withdrawn)
5. (withdrawn)
6. (withdrawn)
- 10 7. (withdrawn)
8. (withdrawn)
9. (withdrawn)
10. (withdrawn)
11. (withdrawn)
- 15 12. (withdrawn)
13. (withdrawn)
14. (currently amended) A method to treat a Herpesviridae viral infection in mammals,
the method comprising:

 ~~contacting~~ receiving an effective amount of a taxane composition to an affected
20 area ~~at least one of a plurality of compositions targeting a microtubule process in~~
~~mammalian cells, the effective amount to reduce the affected area being delivered~~
~~by a topical route of administration to reduce viral infections in dermal lesions~~




25315

PATENT TRADEMARK OFFICE

- 2 -

RNBO-1-1003ROA21

BLACK LOWE & GRAHAM ^{PLLC}


701 Fifth Avenue, Suite 4800
Seattle, Washington 98104
206.381.3300 • F: 206.381.3301

~~and inflamed areas for viruses utilizing the microtubule processes in mammalian cells.~~

15. (currently amended) The method of Claim 14, wherein the taxane composition is applied to the affected area that includes at least one of the group consisting of dermal lesions, inflamed dermal tissue, and dermal tissue exhibiting prodromal symptoms of itching and tingling. ~~plurality of compositions targeting the microtubule process in mammalian cells~~ includes taxanes, ~~taxoids, discodermolide, epothilones A, epothilone B, eleutherobin, taccalonolide, colchicine, colemid, demecolcine, vincristine, vinepidine, vindesine, vinblastine, vinorelbine, desformyl vincristine, desacetyl desformyl vincristine, vinflunine,~~
10 ~~phomopsin A, ustiloxins, cryptophycins, halichondrins, estramustine, rhizoxin, and nocodazole.~~

16. (currently amended) The method of Claim 14, wherein the ~~plurality of compositions~~ composition further includes at least one of the group consisting of solubilizers, lubricants, emulsifiers, waxes, solutions, preservatives, humectants, and analgesics .

15 17. (currently amended) The method of Claim 16, wherein the solutions ~~includes parenteral are water based and~~ includes at least one of the group consisting of saline, lactose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, and syrup.

20 18. (currently amended) The method of Claim 16, wherein the solubilizers includes at least one of the group consisting of dimethyl sulfoxide (DMSO), alcohol, petrolatum, and corn oil.



25315

PATENT TRADEMARK OFFICE

19. (currently amended) The method of Claim 14, wherein the affected area is caused by
herpes viruses utilizing the microtubule process in mammalian cells and includes at least
one of the group consisting of ~~Herpesvirus 1 (HSV-1), Herpesvirus 2 (HSV-2),~~
~~Cytomegalovirus (CMV), Varacella-Zoster Virus (VZV), and Epstein Barr virus (EBV),~~
5 ~~Herpes Simplex 6 (HSV 6), Herpes Simplex 7 (HSV 7), and Herpes Simplex 8 (HSV 8),~~
~~human Papilloma Virus (HPV), Vaccinia Virus (VV), Adenovirus, Parvovirus, Human~~
~~Infectivity Virus (HIV), and rabies virus.~~

20. (currently amended) The method of 14, whereby contacting the taxane composition
~~the topical route of administration~~ comprises contacting rubbing the dermal lesions and
10 ~~inflamed areas with the taxane composition at least one of the plurality of compositions,~~
~~rubbing the composition into the affected area dermal lesions, and inflamed dermal tissue~~
~~areas, and re-contacting and re-rubbing with the composition dermal lesions and inflamed~~
~~areas until the affected area dermal lesions and inflamed areas are is resolved reduced.~~

21. (new) A method to treat a Herpesviridae viral infection in mammals, the method
15 comprising:

contacting an effective amount of a taxane composition to a Herpes virus affected
dermal area to reduce the affected area.

22. (new) The method of Claim 21, wherein the affected area includes at least one of the
group consisting of dermal lesions, inflamed dermal tissue, and dermal tissue exhibiting
20 prodromal symptoms of itching and tingling.

23. (new) The method of Claim 22, wherein the dermal lesions, inflamed areas, and
dermal tissue exhibiting prodromal symptoms of itching and tingling are caused by herpes
viruses that includes at least one of the group consisting of HSV-1, HSV-2, CMV, and EBV.




25315

PATENT TRADEMARK OFFICE

- 4 -

RNBO-1-1003ROA21

BLACK LOWE & GRAHAM ^{PLLC}


701 Fifth Avenue, Suite 4800
Seattle, Washington 98104
206.381.3300 • F: 206.381.3301

24. (new) The method of Claim 21, wherein the taxane composition further includes at least one of the group consisting of solubilizers, lubricants, emulsifiers, waxes, solutions, preservatives, humectants, and analgesics.

25. (new) The method of Claim 24, wherein the solutions includes at least one of the group consisting of saline, lactose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, and syrup.

26. (new) The method of Claim 21, whereby contacting the taxane composition comprises rubbing the composition into the affected area, and re-contacting and re-rubbing with the taxane composition until the affected area is reduced.

27. (new) A method to treat a herpes virus infection in mammals, the method comprising:

contacting an effective amount of a taxane composition to an affected area infected with at least one virus of the group consisting of HSV-1, HSV-2, CMV, and EBV to reduce the affected area.

28. (new) The method of Claim 27, wherein the affected area includes at least one of the group consisting of dermal lesions, inflamed dermal tissue, and dermal tissue exhibiting prodromal symptoms of itching and tingling.

29. (new) The method of Claim 27, wherein the taxane composition further includes at least one of the group consisting of solubilizers, lubricants, emulsifiers, waxes, solutions, preservatives, humectants, and analgesics.

30. (new) The method of Claim 29, wherein the solutions includes at least one of the group consisting of saline, lactose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium




25315

PATENT TRADEMARK OFFICE

- 5 -

RNBO-1-1003ROA21

BLACK LOWE & GRAHAM ^{PLLC}


701 Fifth Avenue, Suite 4800
Seattle, Washington 98104
206.381.3300 • F: 206.381.3301

phosphate, alginates, tragacanth, gelatin, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, and syrup.

31. (new) The method of Claim 27, whereby contacting the taxane composition comprises rubbing the composition into the affected area, and re-contacting and re-rubbing
5 with the taxane composition until the affected area is reduced



25315

PATENT TRADEMARK OFFICE

- 6 -

RNBO-1-1003ROA21

BLACK LOWE & GRAHAM^{PLLC}



701 Fifth Avenue, Suite 4800
Seattle, Washington 98104
206.381.3300 • F: 206.381.3301